Find in Library

Pulmonary toxicity is rarely associated with paclitaxel chemotherapy and its mechanism is not well known. This report describes one patient with pancreatic adenocarcinoma, metastatic neuroendocrine low-grade pancreatic tumor, and a concomitant stage I non-small cell lung cancer (NSCLC), who also developed life-threatening paclitaxel-induced chronic fibrosing interstitial pneumonitis. Giving the gravity of the condition and the not-wellestablished treatment, physicians should be aware of the possibility of chronic fibrosing interstitial lung disease during the course of paclitaxel containing regimens in patients who present with respiratory symptoms.